Bourbeau Matthew P, Bartberger Michael D
Department of Medicinal Chemistry, and Department of Molecular Structure and Characterization, Amgen, Inc. , 1 Amgen Center Drive, Thousand Oaks, California 91320, United States.
J Med Chem. 2015 Jan 22;58(2):525-36. doi: 10.1021/jm500695e. Epub 2014 Nov 3.
The development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease has been pursued by the pharmaceutical industry for some time. A number of recent disclosures describing potent ACC inhibitors have been reported by multiple research groups. Unlike many prior publications in this area, more recent publications contain a significant amount of in vivo efficacy data generated by long-term experiments in rodent models of metabolic disease. Additionally, one compound has been advanced to human clinical studies. The results from these studies should allow researchers to better gauge the potential utility of ACC inhibition for the treatment of human disease.
一段时间以来，制药行业一直在致力于开发用于治疗代谢性疾病的乙酰辅酶A羧化酶（ACC）抑制剂。多个研究小组已报告了一些描述强效ACC抑制剂的最新披露。与该领域许多先前的出版物不同，最近的出版物包含了大量在代谢性疾病啮齿动物模型中长期实验产生的体内疗效数据。此外，一种化合物已进入人体临床研究阶段。这些研究结果应能让研究人员更好地评估ACC抑制在治疗人类疾病方面的潜在效用。
